Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

aTYR PHARMA (ATYR) Restructuring Costs (2024 - 2025)

aTYR PHARMA (ATYR) has disclosed Restructuring Costs for 2 consecutive years, with $2.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Restructuring Costs fell 2.6% year-over-year to $2.8 million, compared with a TTM value of $13.7 million through Dec 2025, up 20.42%, and an annual FY2025 reading of $13.7 million, up 20.42% over the prior year.
  • Restructuring Costs was $2.8 million for Q4 2025 at aTYR PHARMA, down from $3.9 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $3.9 million in Q2 2025 and bottomed at $2.8 million in Q2 2024.